La catena delle opzioni mostra i dati chiave delle opzioni azionarie di HUTCHMED (China) a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per HUTCHMED (China)..

HUTCHMED (China) (NASDAQ:HCM) Azioni, Catena delle Opzioni

HUTCHMED (China)

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China) Ltd

HCM ACQUISITION CORP USD CL A ORD SHS

HCM ACQUISITION CORP USD UNITS CONSISTING ONE CL A ORD SH OF $0.0001 PAR VALUE &

HCM ACQUISITION CORP USD RED WTS

HEALTHIER CHOICES MGMT by Healthier Choices Management Corp.

Healthier Choices Management Corp

Holcim Ltd

Direxion Shares ETF Trust Direxion HCM Tactical Enhanced US ETF

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) raises FY2024 sales outlook from $140.00 million-145.00 million to $143.00 million-145.00 million.

News

Guidance

ADPT

Adaptive Biotechnologies Raises FY2024 Sales Guidance from $140.00M-145.00M to $143.00M-145.00M

Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 47.5 percent increase over losses of $(0.40) per share from the same period last year.

Earnings

Earnings Misses

RGLS

Regulus Therapeutics Q3 EPS $(0.21) Misses $(0.17) Estimate

Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) reported its first-quarter results after Thursday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/24/11/b41823677/affirm-reports-first-fiscal-quarter-2025-results">figures from the quarter.   </a>
The Details: Affirm reported quarterly losses of 31 cents per share, which beat the analyst consensus estimate for losses of 35 cents. Quarterly revenue came in at $698.47 million which beat the analyst consensus estimate of $664.01 million and is an increase over sales of $496.54 million from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
&#8220;We continued driving accelerated growth while delivering consistent credit outcomes and managing the business to our target of 3-4% RLTC as a percentage of GMV, which stood at 3.8% this quarter. Year-over-year GMV growth re-accelerated, and growth in active consumers accelerated for the third consecutive quarter,&#8221; said Max Levchin, Affirm&#8217;s CEO.
&#8220;Transactions per active consumer grew 25% year over year to 5.1, and trailing 12-month GMV per active consumer grew 11% year over year to $1,500. We continue to expect to reach GAAP Operating Income profitability in FQ4'25,&#8221; Levchin added.
Outlook:&nbsp;Affirm sees second-quarter revenue of between $770 million and $810 million and fiscal year 2025 GMV of more than $34 billion. 
AFRM Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Affirm shares are down 0.71% after-hours at $48.45 at the time of publication Thursday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Movers

AFRM

Affirm Reports Better-Than-Expected Q1 Results: Details

WIIM

INOD

Innodata shares are trading higher after the company reported better-than-expected Q3 financial results.

Lions Gate Entertainment Corporation Class B Non-Voting Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.65) by 33.85 percent. The company reported quarterly sales of $948.600 million which missed the analyst consensus estimate of $956.789 million by 0.86 percent. This is a 6.63 percent decrease over sales of $1.016 billion the same period last year.

Earnings Beats

Lions Gate Entertainment Corporation Class B Non-Voting Shares

LGF/B

Lions Gate Entertainment Corporation Class B Non-Voting Shares Q2 2025 Adj. EPS $(0.43) Beats $(0.65) Estimate, Sales $948.600M Miss $956.789M Estimate

Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.58) by 27.59 percent. The company reported quarterly sales of $2.17 million which beat the analyst consensus estimate of $648.50 thousand by 234.62 percent. This is a 134.85 percent increase over sales of $924.00 thousand the same period last year.

DNTH

Dianthus Therapeutics Q3 2024 GAAP EPS $(0.74) Misses $(0.58) Estimate, Sales $2.17M Beat $648.50K Estimate

89bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.64) by 117.19 percent. This is a 208.89 percent decrease over losses of $(0.45) per share from the same period last year.

ETNB

89bio Q3 EPS $(1.39) Misses $(0.64) Estimate

Agilon Health shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 60 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $641.141 thousand which beat the analyst consensus estimate of $375.000 thousand by 70.97 percent. This is a 73.91 percent decrease over sales of $2.457 million the same period last year.

CODX

Co-Diagnostics Q3 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $641.141K Beat $375.000K Estimate

ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $171.33 million which beat the analyst consensus estimate of $160.42 million by 6.80 percent. This is a 43.96 percent increase over sales of $119.01 million the same period last year.

ACVA

ACV Auctions Q3 EPS $(0.10) Beats $(0.11) Estimate, Sales $171.33M Beat $160.42M Estimate

Retail Sales

PRCH

Porch Group Announced That It Lowered Its FY24 Sales Guidance From $450M-470M to $440M-455M

SGHT

Sight Sciences Sees FY24 Revenue $81M-$83M Vs $82.16M Estimate

Eventbrite (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) raises FY2024 sales outlook from $318.00 million-325.00 million to $322.00 million-326.00 million.

Eventbrite Raises FY2024 Sales Guidance from $318.00M-325.00M to $322.00M-326.00M  VS Est.322.03M

Stock Split

ANET

Arista Approved Four-For-One Forward Stock Split

RIGL

Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.42 by 7.14 percent. The company reported quarterly sales of $231.358 million which beat the analyst consensus estimate of $223.537 million by 3.50 percent. This is a 5.44 percent increase over sales of $219.419 million the same period last year.

CARG

CarGurus Q3 2024 Adj. EPS $0.45 Beats $0.42 Estimate, Sales $231.358M Beat $223.537M Estimate

ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively.

ADMA

ADMA Biologics FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively

BSLK

Bolt Projects Holdings Q3 EPS $0.32

UPLD

Upland Software shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.10 by 80 percent. This is a 200 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $161.23 million which missed the analyst consensus estimate of $162.25 million by 0.63 percent. This is a 37.44 percent decrease over sales of $257.73 million the same period last year.

GDEN

Golden Entertainment Q3 EPS $0.18 Beats $0.10 Estimate, Sales $161.23M Miss $162.25M Estimate

Hutchison China MediTech Non-GAAP EPS of $0.50, revenue of $420M

Hutchison China MediTech GAAP ADS of $0.15, revenue of $305.68M

HUTCHMED (China) Limited 2024 Q2 - Results - Earnings Call Presentation

HUTCHMED (China) Limited (HCM) Q2 2024 Earnings Call Transcript

HUTCHMED (HCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Paul Choi from Goldman Sachs...

Hold Rating on HUTCHMED Amid Promising U.S. Launch and Pending EU Reimbursement Clarity

HUTCHMED (China) Limited (HCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on August 2. Analyst Jill W...

Robust Sales and Expansion Potential Underpin Buy Rating for HUTCHMED

Hutchmed Growing Sales By 64% In H1 2024

HUTCHMED pulls regulatory submission for Takeda-partnered cancer drug in China

Chinese biotechs gain as drugmakers targeted in new security bill said to mull divestments

Hutchmed (HCM) announced that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies...

Hutchmed announces new, updated data from sovleplenib ESLIM-01 trial

BGNE

HMDCF

IMAB

WUXIF

WXIBF

WXXWY

ZLAB

Press Releases

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

Health Care

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

General

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

Contracts

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

Opinion

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

Comments

HUTCHMED (China)

HUTCHMED (China) (HCM) Opzioni

HUTCHMED (China) (NASDAQ:HCM) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO